Kura Oncology's GTB-3650 Advances Immunotherapy for Blood Cancer Treatment

GT Biopharma Advances Immunotherapy in Blood Cancer Treatment

GT Biopharma, Inc. is making significant headway in the fight against blood cancers with its innovative immunotherapy drug, GTB-3650. The company has recently completed a safety review for the third dosing group of its Phase 1 clinical trial, reporting no safety or tolerability issues among participants. This pivotal milestone enables GT Biopharma to progress to Cohort 4, where patients will receive a dose of 10μg/kg/day. Screening for new patients is currently underway, and dosing is expected to commence shortly, marking a crucial step in the trial's development.

The Phase 1 study primarily targets patients suffering from relapsed or refractory blood cancers, particularly those with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These patients often face dire circumstances, having either not responded to previous treatments or having experienced a recurrence. GTB-3650 works by enhancing the body’s natural killer (NK) cells, which play a vital role in identifying and destroying malignant cells. The treatment involves continuous infusions over a two-week period, followed by a two-week rest. This regimen can be repeated for up to four months, depending on how patients respond, thus providing a potentially flexible treatment option for those battling these aggressive cancer forms.

Early results from the trial are promising, with six patients treated across initial cohorts exhibiting good tolerability at increasing doses. Observations of favorable trends in immunological biomarkers further bolster the company's confidence in Cohort 4’s dosing as a potential threshold for clinical efficacy. This progress comes at a time when the FDA has approved the first once-daily menin inhibitor for patients with relapsed NPM1-mutated AML, underscoring the increasing acceptance and demand for targeted therapies in the blood cancer treatment landscape. GT Biopharma plans to provide a comprehensive update on its findings and progress in early 2026, as it strives to address some of the most challenging conditions within oncology.

In addition to its advancements, GT Biopharma's commitment to addressing complex cancer types aligns with a broader industry trend toward immunotherapy. The growing recognition of the importance of targeted treatments reflects a shift in how the medical community approaches blood cancers, emphasizing the need for innovative solutions that can offer new hope for patients. As the company moves forward, its focus on enhancing the body’s immune response could redefine treatment paradigms for blood malignancies, contributing to the ongoing evolution of cancer care.